Acadian Asset Management
TERN

Acadian Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Acadian Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Sell
98
-188,927
-100% -$7.76M ﹤0.01% 1989
2025
Q4 		$7.63M Buy
+189,025
New +$4.37M 0.01% 542
2024
Q4 		– Sell
-19,436
Closed -$162K – 2153
2024
Q3 		$162K Buy
+19,436
New +$160K ﹤0.01% 1439
2023
Q1 		– Sell
-22,599
Closed -$229K – 1975
2022
Q4 		$229K Buy
22,599
+9,972
+79% +$66.4K ﹤0.01% 1247
2022
Q3 		$74K Hold
12,627
– – ﹤0.01% 1431
2022
Q2 		$31K Buy
+12,627
New +$25.2K ﹤0.01% 1567

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Acadian Asset Management's TERN Position: Q1 2026 in Review

Acadian Asset Management reduced its Terns Pharmaceuticals (TERN) stake by 100% in Q1 2026, selling an estimated $7.76M and leaving 98 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Acadian Asset Management first reported a position in TERN in Q2 2022 and has held it in 6 quarters since. The position peaked at $7.63M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Acadian Asset Management held 98 shares of Terns Pharmaceuticals worth $5K as of Q1 2026.
  • Acadian Asset Management sold 188,927 Terns Pharmaceuticals shares in Q1 2026, an estimated $7.76M.
  • Terns Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1989 holding.
  • Acadian Asset Management first reported a position in Terns Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
  • Acadian Asset Management's Terns Pharmaceuticals position peaked at $7.63M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.